null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.01x Total Debt / Equity (Conservative)

Neogen carries ~$550M debt post-3M food safety acquisition; 20bp rate rise adds ~$1.1M annual interest expense, modest but manageable given ~$200M EBITDA run-rate

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

China-sourced reagent chemicals and India-sourced API raw materials represent key chokepoints given export controls and geopolitical tension risks

Top-3 international markets (EU-Euro, Brazil-BRL, UK-GBP) expose ~40% of revenue to currency devaluation; EUR and GBP volatility most material given revenue concentration

~45% revenue international; EUR depreciation most impactful (~20% of revenue), followed by GBP (~10%) and BRL (~5%); natural hedges limited, translation risk significant

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs; however, specialty antibody and enzyme suppliers for diagnostic kits represent non-trivial substitution barriers (~6-12 month switching lag)

Neogen is not cloud-infrastructure-dependent operationally; a 30-day cloud termination would disrupt SaaS-based food safety software but not core diagnostic product manufacturing

Secondary digital tools (AccuPoint data management, Neogen Analytics) would face disruption, but represent <10% of revenue; physical product sales unaffected

Low API coupling risk; Neogen's revenue is predominantly physical diagnostic kits and consumables; software APIs are proprietary and internally managed with minimal third-party dependency

Neogen's revenue model is product and service sales; no investment contract, profit-sharing, or token structure exists; Howey Test risk is effectively zero

Very High

Moderate GDPR exposure via EU food safety software clients; CCPA exposure limited; primary products are physical goods reducing data compliance burden materially

Post-3M Food Safety acquisition increased market share in pathogen detection to ~35% globally; EU and DOJ scrutiny possible but no active investigations reported; moderate flag

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Approximately 30-35% recurring (consumables/reagent refills, software subscriptions); 65-70% transactional (equipment, kit purchases); recurring base growing post-3M integration

Razor-and-blade model: instruments placed, consumable reagents and test kits drive recurring pull-through revenue; software adds subscription layer on top

Pricing tied to regulatory compliance mandates, reducing elasticity; consumable pricing stable but equipment competitive; 5-7% annual price increases absorbed historically without significant volume loss

7/10; regulatory necessity and switching costs support above-inflation pricing; competition from bioMérieux and Hygiena caps upside; branded diagnostics command 15-20% premium

47.1% Gross Margin (Strong (40-60%))

Minimal free-rider leakage; products are proprietary consumables requiring Neogen instruments; customers cannot access testing capability without purchasing Neogen inputs

Revenue growth is moderately sublinear; manufacturing scale and software leverage allow 15-20% revenue growth with ~8-10% headcount growth; post-3M synergies accelerating this ratio

Marginal cost of growth declining as 3M Food Safety integration matures; fixed manufacturing overhead spread over higher volume drives improving gross margins toward 50%+ target

Not applicable; Neogen operates no franchise network; distribution is through direct sales force and authorized distributors with standard commercial compliance requirements

At 10x scale, CAC efficiency improves via brand recognition and regulatory entrenchment; however, global sales force expansion costs remain significant; estimated CAC:LTV ratio ~1:8

Weak direct network effects; indirect effects exist via regulatory standard-setting influence and industry data aggregation; durability moderate as standards entrench incumbent solutions

-32.9% Return on Assets (Negative equity)

Tier 1 recession-resistant; food safety testing is regulatory-mandated regardless of economic cycle; FSMA and EU food law compliance drives non-discretionary demand

Large food and beverage manufacturers (Tyson, Nestlé, Cargill tier); no single customer >5% of revenue; concentration risk low across diversified global food producer base

Government labs, academic institutions, and veterinary/animal safety testing facilities; fragmented segment providing revenue diversification and reducing single-customer concentration risk

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.2% CapEx / Revenue (Low-CapEx Asset-Light)

0000711377

NEOG